Market Size of Thalassemia Treatment Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 7.60 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Thalassemia Treatment Market Analysis
The thalassemia treatment market studied was projected to grow with a CAGR of nearly 7.6% over the forecast period. The major factors attributing to the growth of the market are increasing prevalence of thalassemia and also growing awareness to treat thalassemia. According to National Center on Birth Defects and Developmental Disabilities, thalassemia, affects at least 1,000 people in the United States. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companies boosting the market growth. Chelation therapy and blood transfusion are the conventional treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion method for purifying blood, raise the possibility of curing thalassemia in patients. However the high cost of the treatment is major drawback for the market growth.